Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Alligator Bioscience: BioStock: Alligator gearing up for new milestones with mitazalimab

Alligator Bioscience

The 52 per cent Objective Response Rate measured with mitazalimab in the phase II OPTIMIZE-1 trial has given Alligator Bioscience positive momentum for continued advancements. The results have put the company on a path towards discussions with regulators for accelerated development of the CD40 agonist. The company now seeks to raise approximately 199 MSEK in a rights issue to deliver its next key value inflection points.

Read the article at biostock.se:

Alligator gearing up for new milestones with mitazalimab - BioStock (https://www.biostock.se/en/?p=46734)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team